Currently, the fixed-duration treatment of obinutuzumab-venetoclax and ibrutinib-venetoclax are viable options for first-line treatment for CLL patients without TP53 aberrations [28,29,30,31]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.